Quick Answer
CytoDyn Inc. reported Operating Income Loss of $9.66 million for the year ending 2025.
- CytoDyn Inc. showed an increase of +153.5% in Operating Income Loss from 2024 to 2025.
- This data is from CytoDyn Inc.'s annual report (Form 10-K), filed with the SEC on July 25, 2025.
- XBRL data for this metric is available from 2011 to 2025 (15 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2013: -$1.00 million | Q4 2013: -$1.60 million | Q1 2014: -$2.88 million | Q3 2014: -$2.95 million | Q4 2014: -$2.99 million | Q1 2015: -$3.29 million | Q3 2015: -$6.66 million | Q4 2015: -$2.89 million | Q1 2016: -$5.05 million | Q3 2016: -$5.36 million | Q4 2016: -$6.16 million | Q1 2017: -$8.02 million | Q3 2017: -$9.81 million | Q4 2017: -$10.78 million | Q1 2018: -$14.14 million | Q3 2018: -$13.49 million | Q4 2018: -$15.69 million | Q1 2019: -$12.87 million | Q3 2019: -$12.63 million | Q4 2019: -$12.12 million | Q1 2020: -$22.08 million | Q3 2020: -$25.57 million | Q4 2020: -$24.50 million | Q1 2021: -$30.79 million | Q3 2021: -$21.64 million | Q4 2021: -$25.32 million | Q1 2022: -$19.40 million | Q3 2022: -$9.71 million | Q4 2022: -$23.16 million | Q1 2023: -$3.92 million | Q3 2023: -$4.61 million | Q4 2023: -$3.40 million | Q1 2024: -$3.41 million | Q3 2024: $22.44 million | Q4 2024: -$3.71 million | Q1 2025: -$4.00 million | Q3 2025: -$4.95 million | Q4 2025: -$21.69 million.
- Over the full 15 years of available data (2011 to 2025), CytoDyn Inc.'s Operating Income Loss has grown by 361.2%.
- Historical annual values: Fiscal year 2025: $9.66 million | Fiscal year 2024: -$18.06 million | Fiscal year 2023: -$40.58 million | Fiscal year 2022: -$145.40 million | Fiscal year 2021: -$104.60 million | Fiscal year 2020: -$74.65 million | Fiscal year 2019: -$55.85 million | Fiscal year 2018: -$45.92 million | Fiscal year 2017: -$27.33 million | Fiscal year 2016: -$21.18 million | Fiscal year 2015: -$19.60 million | Fiscal year 2014: -$8.11 million | Fiscal year 2013: -$7.99 million | Fiscal year 2012: -$7.46 million | Fiscal year 2011: -$3.70 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: